GlassScriptPhysician profile
Todd I Stone
NPI 1114910767
$10,484.96
in general payments reported to CMS, 2019-2025
41 companies · $2,727 in 2025
The $2,727 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,403 · 2022: $1,855 · 2023: $2,109 · 2024: $1,391 · 2025: $2,727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,226.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,198.25 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,190.26 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Astrazeneca Pharmaceuticals LP | $899.57 | 2021-2025 | Airsupra, Breztri, Nexium |
| Otsuka America Pharmaceutical, INC. | $666.25 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $649.26 | 2021-2025 | Fanapt, Hetlioz |
| Lilly USA, LLC | $620.54 | 2021-2025 | Mounjaro, Trulicity, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $429.39 | 2021-2025 | Caplyta |
| Axsome Therapeutics, INC. | $421.76 | 2022-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $383.11 | 2021-2025 | Ingrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $345.79 | 2021-2024 | Jardiance, Tradjenta, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $341.08 | 2021-2025 | |
| Novo Nordisk INC | $333.08 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lundbeck LLC | $330.48 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $294.09 | 2021-2025 | Trintellix |
| Abbott Laboratories | $287.09 | 2021-2023 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $216.78 | 2021-2025 | Invega Sustenna |
| Amgen INC. | $206.40 | 2021-2023 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $200.76 | 2022-2025 | Xifaxan |
| Alkermes, INC. | $194.09 | 2021-2025 | Aristada, Lybalvi |
| Pfizer INC. | $147.82 | 2021-2022 | |
| Corium, LLC | $125.83 | 2022-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $121.13 | 2021-2023 | Verquvo, Belsomra |
| Glaxosmithkline, LLC. | $112.26 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $103.28 | 2024 | Lifevest |
| Novartis Pharmaceuticals Corporation | $93.46 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $75.00 | 2021 | |
| Amarin Pharma, INC. | $61.21 | 2021-2022 | |
| Antares Pharma, INC. | $54.42 | 2021 | |
| Eisai INC. | $52.69 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $48.44 | 2021-2025 | Cobenfy |
| Exact Sciences Corporation | $46.07 | 2024-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $37.78 | 2021 | |
| Inari Medical, INC. | $33.73 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Medtronic, INC. | $30.38 | 2025 | Intellis Adaptivestim |
| Idorsia Pharmaceuticals US INC | $29.62 | 2023 | Quviviq |
| Xeris Pharmaceuticals, INC. | $23.20 | 2022 | |
| Stryker Corporation | $21.45 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Noven Therapeutics, LLC | $17.82 | 2024 | Secuado, Xelstrym |
| Tolmar, INC. | $15.51 | 2025 | Jatenzo |
| Avanir Pharmaceuticals, INC. | $14.39 | 2021 | |
| Clarus Therapeutics INC. | $11.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.